Jefferies analyst David Windley maintained a Hold rating on Catalent (CTLT – Research Report) today and set a price target of $63.50.

Jupiter Neurosciences, Inc. (JUNS) is planning to raise $11 million in an initial public offering (IPO) on the week of November 11th, IPO Scoop reports. The company plans to issue 2,800,000 shares at ...

Welcome to the third-quarter 2024 Novo Nordisk A/S earnings conference call. [Operator instructions] Please be advised that ...

Viatris Inc. today announced that on November 4, 2024, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share of the Company's common stock. The ...

Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced acceptance of an oral ...

Novo Nordisk reported mixed Q3 earnings, but GLP-1 drugs contributed to revenue strength. The company also adjusted its ...

“These efforts are critical to ensure a consistent and high-quality supply of NUZ-001 for both clinical trials and future ...

Nektar Therapeutics is selling its Huntsville, Alabama, manufacturing plant and reagent supply business to private equity ...

Q3 2024 Earnings Call Transcript November 6, 2024 Operator: Good day, and thank you for standing by. Welcome to the Third Quarter 2024 Novo Nordisk A/S Earnings Conference Call. At this time, all ...

Over the last year Novo shares continued to rise due to strong sales growth of its GLP-1 drugs, ongoing expansion into the obesity treatment market, positive clinical trial results ... market in ...

Catalent Inc., a leading global contract development and manufacturing organization (CDMO), is known for its expertise in optimizing product development, launch, and full life-cycle supply for the ...